# Grok 4.7 / mol-d01

Original final answer, shared by both scoring rounds.

Recommendation: Do not interpret catalysis versus scaffolding from M1–M3. First reconfirm K loss and the two phenotypes, then run an isogenic rescue in K-null cells with expression-matched wild-type K versus a quality-controlled kinase-dead K, and pair it with acute catalytic blockade in cells that still contain K protein. Only the joint pattern can support “catalysis is required rather than scaffolding.”

The unvalidated kinase-dead construct in M3 is not yet interpretable. A failed rescue by that construct would not show that catalysis is required.

## Evidence → inference → conclusion

M1. A pooled K knockout lowers phospho-S after ligand stimulation and slows growth. Inference: in that population, the knockout procedure is associated with both phenotypes. That is compatible with K being necessary, but also with off-target edits, adaptation, or mixed clones. A pool reduces single-clone artifacts; it does not identify which molecular function of K matters, and it does not by itself prove that K protein is gone.

M2. Total S is unchanged. Inference: the phospho-S decrease is not explained by loss of S protein. It remains compatible with less phosphorylation of S, more dephosphorylation, or an epitope/localization artifact. It does not show that K phosphorylates S directly.

M3. One kinase-dead construct exists; abundance and folding are unmeasured. Inference: catalytic inactivity, stability, localization, and partner binding are unknown. Using it now cannot discriminate mechanism.

Conclusion. Ligand-induced phospho-S and growth are candidate K-dependent phenotypes, and the phospho-S change is not a trivial loss of S. Whether catalytic activity is required, whether non-catalytic scaffolding is sufficient, and whether scaffolding is dispensable are all untested. Those are three different claims. The study below is built to separate them. No result is claimed from data that were not supplied.

## What the contrast actually tests

Catalytic activity means ATP-dependent phosphotransfer by K. Scaffolding means non-catalytic binding that organizes partners. Wild-type K has both. A valid kinase-dead allele has lost phosphotransfer but retained folding, localization, and partner binding. A valid scaffold-loss allele would retain phosphotransfer but lose binding; no such allele is in the evidence, so it is optional only if an interaction surface is later established.

Rescue logic, if and only if quality control passes:

- Wild-type restores a phenotype and kinase-dead does not: catalytic activity is necessary for that phenotype, and the scaffolding retained by kinase-dead is not sufficient. This does not prove scaffolding is irrelevant. Wild-type still scaffolds, and catalysis may require K’s own binding surfaces.
- Wild-type and kinase-dead restore equally, and kinase-dead is truly inactive: non-catalytic K is sufficient. Catalysis is dispensable for that phenotype.
- Neither restores, while wild-type protein is present and localized: the knockout phenotype is not shown to be caused by loss of K.
- Kinase-dead drives the phenotype below empty-vector null: treat it as a dominant-negative or misfolded protein, not as a clean separation-of-function allele.

Acute blockade is required for the “rather than scaffolding” wording. Inhibitor or analog-sensitive inhibition leaves K protein in place. If selective blockade phenocopies the null, presence of the scaffold is not enough and catalysis is required on the assay timescale. If genetic loss exceeds acute blockade, chronic absence, scaffolding, adaptation, or incomplete inhibition remain possible. Do not collapse phospho-S and growth into one verdict; they can dissociate.

## Discriminating outcome patterns

Read each row only after the quality-control column is true. “Matched KD” means kinase-dead protein matches wild-type for abundance, localization, and partner binding or the best available folding proxy, and is catalytically inactive.

1. Matched wild-type rescues ligand-induced phospho-S and growth; matched kinase-dead rescues neither; acute selective blockade phenocopies the null for both and loses that effect in null cells. Conclusion: catalysis is required for both, and retained scaffolding is not sufficient. This is the pattern that supports the “rather than scaffolding” claim for these endpoints.

2. Both alleles rescue both endpoints equally; acute blockade does not phenocopy the null despite demonstrated target engagement. Conclusion: non-catalytic K is sufficient; catalysis is dispensable for these endpoints.

3. Wild-type rescues phospho-S but not growth; kinase-dead rescues neither; blockade phenocopies only the phospho-S defect. Conclusion: catalysis is required for ligand-induced phospho-S. The growth defect is not explained by that phospho-S change. Do not claim one K function for both phenotypes.

4. Wild-type rescues growth but not phospho-S. Conclusion: these growth and phospho-S phenotypes are separable. Recheck the phospho-S assay window before any mechanistic claim about signaling.

5. Neither allele rescues, wild-type expression and localization pass. Conclusion: stop the claim that the M1 phenotypes are caused by loss of K. Fix reagent identity or treat the association as non-specific.

6. Kinase-dead is unstable, mislocalized, partner-binding-deficient, or still active. Conclusion: no mechanistic call. Failed rescue is uninterpretable.

7. Inhibitor suppresses phospho-S in K-null cells. Conclusion: the compound is off-target for this readout. Drop it. Do not infer scaffolding from failure of a non-selective inhibitor.

8. Blockade hits phospho-S but growth differs between acute blockade and chronic null. Conclusion: report timescale-dependent dissociation. Do not force a single mechanism.

Direct phosphorylation of S is not established by any of these patterns. A cellular requirement can be indirect.

## Assumptions and unreported parameters

Assumptions to state in the protocol, not treat as facts: the parental line is the same biological background as M1; phospho-S is a ligand-dependent, antibody-accessible mark; growth slowing in M1 could be slower division, more death, or both; the kinase-dead mutation does not automatically preserve the scaffold; overexpression can create neomorphic binding.

Not reported, so not invented here: cell-line identity, ligand identity and dose, stimulation time, knockout method and guides, proof that K protein is absent, K expression level, the kinase-dead mutation, whether K phosphorylates S, any inhibitor, partner list, sample size, and variance. Each is handled by a calibration procedure below.

## Operational protocol

Label: proposed experiment. Do not analyze mechanism until the preparation gates pass.

### 1. Preparation and quality checks

1.1. Freeze a reference stock of the parental cancer line used for M1. Record passage. Run mycoplasma testing and a species-appropriate identity check before any arm. Exclude contaminated or misidentified stocks.

1.2. Replication gate for M1–M2. In parental versus the existing pooled knockout, measure K protein, total S, ligand-induced phospho-S, and growth in at least three independent cultures. If K protein is not substantially reduced, stop. M1 has not shown loss of K. If ligand does not raise phospho-S in parental cells, or total S differs enough to explain phospho-S, stop and recalibrate the assay before any rescue.

1.3. Confirm the knockout reagent. Sequence the edited locus or quantify alleles by an orthogonal method. Require at least two independent K-null reagents, or one null plus an orthogonal knockdown, so a single-reagent artifact is not the only basis for rescue. Prefer the pooled population plus a small set of independent null clones as a sensitivity panel, not as the sole evidence.

1.4. Build the isogenic set in the same null background: empty vector; wild-type K; the existing kinase-dead K. Use the same backbone, tag, and promoter. If the knockout can recut the cDNA, introduce silent changes only at the guide site and confirm that those changes do not alter the protein sequence. Do not switch species of K unless same-species rescue fails and that failure is documented.

1.5. Kinase-dead quality control, all proposed, all required before phenotyping:

- Sequence the catalytic mutation.
- Catalytic assay: immunoprecipitate K from null cells expressing wild-type or kinase-dead protein, at matched K input, alongside null empty-vector precipitate as the background. Establish that any phosphate transfer requires added ATP, is absent in the empty-vector precipitate, and is present with wild-type. Kinase-dead must fall to empty-vector background. If no cellular substrate of K is known, do not invent one. Use a substrate only after the wild-type signal is shown to be K-dependent by the empty-vector and matched-input controls. If that K-dependent signal cannot be established, do not call the construct kinase-dead.
- Abundance: titrate dose, multiplicity, or inducer. Accept only cultures in which steady-state K is inside the linear immunoblot range and matched between wild-type and kinase-dead. Define the match window from replicate loading curves in a pilot, not from a single visual blot. Also compare both to parental K and pre-specify an acceptable fold-range relative to parental before unblinding; choose that range from detection linearity and from a pilot in which wild-type rescue is tested across expression levels.
- Folding and scaffolding proxies: if any K interactor is already established in this line, co-immunoprecipitate it from matched wild-type and kinase-dead lysates and require similar recovery after normalizing to immunoprecipitated K. If no interactor is known, do not invent one. Use subcellular localization versus wild-type and a thermal-stability comparison on equal K input as provisional folding checks, and state that partner binding was not tested.
- Localization: same compartment as wild-type by fractionation or immunostaining, scored blind.

1.6. Phospho-S assay gate. Show ligand dependence, loading-control linearity, and antibody specificity by phosphatase treatment of lysate and, if available, phosphopeptide competition. If specificity fails, replace the antibody or use an orthogonal phospho-readout before proceeding. Repeat total S on every experimental blot.

1.7. Acute-blockade gate, conditional. Use a compound or analog-sensitive allele only if cellular target engagement can be shown. Calibration: titrate until K activity measured as in 1.5 is inhibited in K-expressing cells, then test the same doses in K-null cells. If phospho-S falls further in null cells, the tool is off-target for this phenotype; discard it. An inactive analog, if one exists, is a chemical control, not proof of selectivity. Selectivity is the null-cell test. If no tool passes, proceed with rescue only and downgrade the claim as in the limits.

1.8. Ligand and time calibration, parental cells. For phospho-S, run a dose curve and a time course from vehicle to a clearly plateaued stimulus. Choose a dose and time in the rising or early-plateau region where fold-change over vehicle is stable across two pilot days, not a saturated dose that could hide partial rescue. For growth, determine doubling time and a ligand concentration that affects parental growth without killing the culture over the assay window. Do not assume the signaling dose equals the growth dose. Record both.

1.9. Starvation or serum step, only if needed. If basal phospho-S is already high, shorten or lengthen the pre-stimulus withdrawal until basal signal is low, ligand still induces, and viability at the harvest time remains acceptable. Set that duration from the pilot; do not copy an unstated historical time.

### 2. Independent units, allocation, blinding

The independent unit is a biological replicate: a separately recovered transduction or transfection, or an independently grown clone, cultured apart from other replicates. Wells and technical blots are not replicates.

Pre-specify a minimum of three biological replicates for the phospho-S primary contrast. For growth, run a pilot variance estimate on empty-vector versus parental cells and calculate the replicate number required to detect a restoration equal to the M1 growth effect with the lab’s chosen power and alpha. Do not invent that number now. If the pilot variance makes the study infeasible, stop and change the growth metric rather than underpower a claim.

Randomize well and plate positions. Include all genotypes and vehicle versus ligand within each replicate so plate effects are crossed with treatment. Code samples before lysis densitometry, colony or confluence calls, and microscopy. Unblind only after quantification files are locked.

### 3. Intervention and sampling

Signaling arm. Plate the accepted lines at a density taken from the linear-growth pilot. Apply the calibrated pre-stimulus condition, then vehicle or ligand at the calibrated signaling dose. Harvest at the calibrated time. From each culture, take matched lysate for phospho-S, total S, K, and a loading control. Reserve an aliquot for the catalytic or target-engagement assay when the blockade arm is run.

Blockade arm, only if 1.7 passed. Add vehicle, active tool, and inactive analog if available, to parental or wild-type-rescue cells and to null cells, at the null-selective dose. Sample phospho-S on the same schedule. For growth, expose cultures continuously or on the schedule justified by how long target engagement persists in a pilot washout; measure engagement over that schedule rather than assuming continuous inhibition.

Growth arm. Seed at the calibrated density in the growth-medium condition defined in 1.8. Count cells or use a validated confluence method at multiple times spanning at least two parental doublings. In parallel, score a death or viability marker so slower net growth is not mistaken for killing. Keep ligand and serum conditions explicit and identical across genotypes within a replicate.

Do not use the signaling harvest cultures for the multi-day growth curve.

### 4. Measurements

Primary, pre-specified: ligand-induced phospho-S normalized to total S, and growth rate or area under the cell-number curve, each analyzed separately. Always report total S and K abundance.

Secondary: death marker; basal phospho-S without ligand; K localization in the same samples if staining is done.

Exploratory, not required for the decision: additional phosphoproteins, transcripts, or phosphoproteomics. These may suggest intermediates. They do not replace the rescue contrast.

Antibody or assay failure at this stage returns the study to gate 1.6. Do not substitute an unvalidated band.

### 5. Controls

Required in every replicate: parental; null plus empty vector; null plus wild-type; null plus kinase-dead; vehicle; ligand; loading control; phosphatase-treated specificity control on at least one lysate per batch. Blockade replicates also include null cells exposed to the tool. Expression-matched wild-type is the positive rescue control. Empty vector is the negative control. The catalytic assay is the control that kinase-dead is inactive. Partner binding or the pre-specified folding proxy is the control that it still resembles a scaffold.

### 6. Analysis

Lock the analysis plan before unblinding. Primary genotype contrasts for each endpoint: empty versus wild-type; wild-type versus kinase-dead; empty versus kinase-dead. Test a genotype-by-ligand interaction for phospho-S. Use a model that nests technical measurements within biological replicate. Correct for the pre-specified family of primary contrasts.

Normalize within blot to the loading control. Express phospho-S as a ratio to total S. Set the reference condition in the plan, preferably parental-plus-ligand or wild-type-rescue-plus-ligand, and do not switch after seeing results. Report effect sizes and confidence intervals.

“Kinase-dead equals wild-type” is an equivalence claim, not a non-significant difference. Set the equivalence margin before unblinding from pilot variance and from the smallest restoration fraction the lab considers biologically meaningful. That fraction is a decision threshold to be declared, not a value supplied by M1–M3.

Do not average phospho-S and growth into a composite score. A dissociation is a result.

### 7. Acceptance and stopping

Stop or do not claim mechanism if any of these occur: K protein persists in the knockout; ligand fails to induce specific phospho-S in parental cells; wild-type protein is absent or grossly mislocalized; kinase-dead remains catalytically active or fails the abundance, folding, localization, or partner-binding gate; the phospho-antibody fails specificity; the inhibitor suppresses the readout in null cells.

Accept a catalysis-required conclusion for a given endpoint only if wild-type rescues that endpoint, matched kinase-dead does not, quality control passed, and the result replicates across the pre-specified biological replicates and at least two independent null reagents or rescue batches. Accept the stronger “rather than scaffolding” conclusion only if, in addition, acute selective blockade phenocopies the null and does not act in null cells.

Accept a scaffolding-sufficient, catalysis-dispensable conclusion only if matched, catalytically inactive kinase-dead restores the endpoint to within the equivalence margin of wild-type, and acute blockade either is unavailable and the claim is downgraded accordingly, or engages K without phenocopying the null.

If wild-type does not rescue, do not proceed to a catalytic story. Troubleshoot expression first. If expression passes and wild-type still fails, conclude that M1 has not been shown to be K-specific.

### 8. Troubleshooting

Expression above the parental range: retitrate down and repeat the rescue pilot. Interpretation at non-physiological overexpression is not acceptable for the primary claim.

Kinase-dead unstable or partner-binding-deficient: do not interpret. As a proposed alternative reagent, make a second catalytic-site mutant at a different conserved catalytic residue, then repeat the full quality-control gate. Do not assume the residue class preserves the scaffold.

Dominant-negative kinase-dead: lower expression into the matched window. If suppression below empty vector persists at matched abundance, exclude that allele.

No K-dependent phosphate-transfer assay: do not label any mutant kinase-dead. Consider an analog-sensitive allele as an alternative acute tool, with the same null-selectivity logic, rather than inventing a substrate.

Growth confounded by density or edge effects: reseed from the exponential-growth calibration and keep randomized positions. If death accounts for the M1 growth effect, report survival separately and do not call it a proliferation requirement.

Blot saturation: load a standard curve on each gel and quantify only in the linear range.

Rescue recut by knockout machinery: confirm cDNA integrity in the final cells. If the cDNA is edited, rebuild with silent protection and repeat.

Acute and chronic results disagree: report both. Do not average them. Consider adaptation as a live alternative.

## Alternatives

If no selective inhibitor can be calibrated, an analog-sensitive K allele plus a bulky inhibitor analog is the cleanest acute substitute. It is a proposed build, not a reagent in the evidence. It still needs a cellular engagement assay and a null or analog-insensitive control.

A degrader-versus-inhibitor comparison can support the same logic only after each tool passes the null-cell selectivity gate. Degrader removes scaffold and enzyme; inhibitor should block only catalysis. That comparison is not licensed by M1–M3 alone.

A scaffold-defective, catalysis-intact mutant would test whether scaffolding is necessary. Do not design it until a real binding surface is known. Random surface mutations are not a control.

An in vitro test of whether K can modify S addresses directness only. It does not answer the cellular requirement question.

## Limits and what would change the recommendation

This design cannot establish that K phosphorylates S in cells, that the result holds in other lines, or that either phenotype matters in animals. Pooled knockout effects may include adaptation that acute rescue does not reverse. A kinase-dead point mutant can alter conformation and scaffolding even when a co-immunoprecipitation looks similar. Matching one partner does not match the interactome. Overexpression can bypass normal localization. Phospho-S antibody signal is not stoichiometry unless an orthogonal quantitative method is added. Growth assays confound division and death unless both are measured. Equivalence margins chosen too loosely can call a partial catalytic rescue “scaffolding.”

Change the recommendation if: K protein is not lost; wild-type K cannot rescue; no kinase-dead allele can be shown inactive and folded; or no acute tool is selective. In those cases the honest output is “K function unassigned,” not a catalytic conclusion. Change the claim from “rather than scaffolding” to “catalysis is necessary and kinase-dead scaffolding is not sufficient” if rescue is clean but acute blockade cannot be performed. Upgrade toward a direct-substrate model only with new evidence that K modifies S in cells and that an S site mutant phenocopies the relevant endpoint. That evidence is not in the packet.
